Gyre Therapeutics, Inc. GYRE Increase (Decrease) in Notes Receivables
Increase (Decrease) in Notes Receivables at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInNotesReceivables.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s increase (decrease) in notes receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s increase (decrease) in notes receivables?
- Gyre Therapeutics, Inc. (GYRE) reported increase (decrease) in notes receivables of -$1.9M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s increase (decrease) in notes receivables changed year-over-year?
- Gyre Therapeutics, Inc.'s increase (decrease) in notes receivables increased by 15.2% year-over-year, from -$2.24M to -$1.9M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s increase (decrease) in notes receivables?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s increase (decrease) in notes receivables has grown at a 1.5% compound annual growth rate (CAGR), from -$1.11M to $1.15M.
- What does increase (decrease) in notes receivables mean?
- Tracks the net change in the balance of notes receivable, representing formal debt instruments owed to the company by third parties. This metric indicates the company's extension of credit or the collection of debt over a specific period. It is used to assess working capital management and credit exposure.